Drug intelligence / Profile preview

anti-G-CSF neutralizing antibody

Development stage
Preclinical
Lead developer
R&D Systems
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous, Subcutaneous, Intraperitoneal
01

Overview

An anti-G-CSF neutralizing antibody is a monoclonal antibody designed to bind to and inhibit the biological activity of Granulocyte Colony-Stimulating Factor (G-CSF, or CSF3). G-CSF is a critical cytokine that regulates the production, differentiation, and mobilization of neutrophils from the bone marrow. While G-CSF itself is a widely used therapeutic for treating neutropenia, neutralizing antibodies against the ligand are primarily employed as research tools to investigate the role of G-CSF in pathological conditions. Preclinical research suggests that blocking G-CSF may be beneficial in treating autoimmune and inflammatory diseases, such as rheumatoid arthritis and neutrophilic dermatoses, as well as in certain cancers where G-CSF-driven myelopoiesis contributes to an immunosuppressive tumor microenvironment. These antibodies function by preventing G-CSF from binding to its cognate receptor (G-CSFR/CSF3R), thereby attenuating neutrophil-mediated inflammation.

Other names
anti-G-CSF antibodyanti-CSF3 antibodyanti-CSF-3 antibodyanti-CSF 3 antibodyG-CSF neutralizing antibody
02

Targets

G-CSF (Granulocyte colony-stimulating factor)

Beyond the preview

Go deeper on anti-G-CSF neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-G-CSF neutralizing antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call